Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43

NCT01563263 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

803

Enrollment

INDUSTRY

Sponsor class

Conditions

Pseudomonas Aeruginosa Infection

Interventions

BIOLOGICAL: IC43
DRUG: Placebo

Sponsor

Valneva Austria GmbH